Citations

Clear

1526 citation(s) found for "Sun, Yu".

The risks of cancer in older women with BRCA pathogenic variants: How far have we come?
Metcalfe, Kelly , McCuaig, Jeanna , Eisen, Andrea , Elser, Christine , Senter, Leigha , Møller, Pål , Bordeleau, Louise , Velsher, Lea, Zakalik, Dana , Olopade, Olufunmilayo I. , Cullinane, Carey A., Sun, Ping , Narod, Steven A. , Metcalfe, Kelly A , Olopade, Olufunmilayo I , Kotsopoulos, Joanne , Narod, Steven A , Senter, Leigha , Eisen, Andrea , Bordeleau, Louise , Gronwald, Jacek , Tung, Nadine , Foulkes, William D. , Neuhausen, Susan L. , Fruscio, Robert , Eng, Charis , Pal, Tuya , Couch, Fergus J. , Kotsopoulos, Joanne , Lubiński, Jan

Mayo Clinic

Cancer | December 26, 2022 | Volume: 129 | Issue: 6 | Pages: 901-907

10.1002/cncr.34615 | PMID 36571512 Get It

AbstractBackgroundThe purpose of this study was to estimate the cumulative risks of all cancers in women from 50 to 75 years of age with a BRCA1 or BRCA2 pathogenic variant.MethodsParticipants were women with BRCA1 or BRCA2 pathogenic variants from 85 centers in 16 countries. Women were eligible if they had no cancer before the age of 50 years. Participants completed a baseline questionnaire and follow‐up questionnaires every 2 years. Women were followed from age 50 until a diagnosis of cancer, death, age 75, or last follow‐up. The risk of all cancers combined from age 50 to 75 was estimated using the Kaplan–Meier method.ResultsThere were 2211 women included (1470 BRCA1 and 742 BRCA2). There were 379 cancers diagnosed in the cohort between 50 and 75 years. The actuarial risk of any cancer from age 50 to 75 was 49% for BRCA1 and 43% for BRCA2. Breast (n = 186) and ovarian (n = 45) were the most frequent cancers observed. For women who had both risk‐reducing mastectomy and bilateral salpingo‐oophorectomy before age 50, the risk of developing any cancer between age 50 and 75 was 9%.ConclusionWomen with a BRCA1 or BRCA2 pathogenic variant have a high risk of cancer between the ages of 50 and 75 years and should be counselled appropriately.
Dynamic monitoring of minimal residual disease in newly‐diagnosed multiple myeloma
Yang, Pei‐Yu , Xu, Weiling , Liang, Xinyue , Yu, Shanshan , Yi, Xingcheng , Liu, Mengmeng , Tian, Mengru, Yue, Tingting , Yan, Yurong, Hu, Zhongli, Zhang, Nan , Wang, Jingxuan , Hu, Rui , Kumar, Shaji , Jin, Fengyan , Kumar, Shaji K , Dai, Yun , Jin, Fengyan , Yue, Tingting, Zhang, Yingjie , Guo, Qiang , Sun, Xiaoxiao , Dai, Yun

Mayo Clinic

American Journal of Hematology | December 21, 2022 | Volume: 98 | Issue: 3 | Pages: No page available

10.1002/ajh.26810 | PMID 36540935 Get It

Unified Parkinson’s Disease Rating Scale (UPDRS) motor score subscale trajectories in Dementia with Lewy Bodies and Parkinson Disease Dementia in a community autopsy cohort
Adler, Charles, Shill, Holly A. , Mehta, Shyamal, Driver‐Dunckley, Erika, Choi, Alexander S., Belden, Christine M. , Goldfarb, Danielle, Beach, Thomas G. , Choudhury, Parichita , Zhang, Nan , Chen, Kewei , Shprecher, David , Mehta, Shyamal H. , Driver‐Dunckley, Erika , Choi, Alexander, Serrano, Geidy E. , Atri, Alireza

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S7 | Pages: No page available

10.1002/alz.066727 Get It

AbstractBackgroundWe previously reported that in our autopsy‐confirmed cohort of Dementia with Lewy Bodies (DLB), Parkinson’s Disease Dementia (PDD) and Alzheimer’s Disease (AD), DLB with parkinsonism (DLB+Park) predicted faster progression of UPDRS‐III scores compared to PDD, DLB without parkinsonism (DLB‐Park), and AD. This study examined annualized rate of change of UPDRS‐III subscales in our cohort.MethodsData included were from participants in Arizona Study of Aging and Neurodegenerative Diseases (AZSAND) with clinicopathologic diagnosis of DLB (n = 48), PDD (n = 98) or pure AD (n = 48), and longitudinal movement exams. Mixed effects model (accounting for age, education, and sex) was used to determine predicted mean UPDRS‐III and subscale scores (0‐4) for all groups. Individual UPDRS‐III subscale scores were derived for: Body Bradykinesia, Limb Bradykinesia, Gait, Postural Instability, Limb Rest Tremor, Neck Rigidity and Limb Rigidity. Where applicable, scores for multiple limbs involved were averaged.ResultsLongitudinal data was analyzed for over 1430‐participant years. Parkinsonism was present in 65.6% of DLB participants. PDD participants were more likely to be treated with dopaminergic agents (87.8%) compared to (p<0.001) DLB+Park (57.6%), DLB‐park (0%) and AD (2.1%). Frequency (29.4% vs. 29.0%) and severity (mean±SE = 0.4±0.07 and 0.4±0.12) of Limb Rest Tremor was similar for PDD and DLB+park. Limb Bradykinesia frequency and severity were PDD: 100%, 2.4±0.11, DLB+Park: 96.8%, 2.1±0.18, DLB‐Park: 20%, 0.4±0.23, and AD: 62%, 1.1±0.16. Frequency of gait abnormality was 98.5% in PDD, 90.3% in DLB+park, 60% in DLB‐Park and 57.8% in AD. Rigidity was most frequent in the PDD group (88.2%), followed by DLB+Park (71%), AD (19.6%), and none DLB‐park (0%). Over 8 years trajectories for limb bradykinesia and gait were greater for DLB+park than PDD (Figure 1, Cohen’s d range 0.89‐2.18 and 0.63‐1.99 over 8 years, p<0.001).ConclusionOur results suggest that DLB+Park group have faster motor progression predominantly related to gait abnormalities and limb bradykinesia. Future analyses will explore more convergent data, integrated effects of various measures and their differential contributions in this cohort.
Development and Validation of a clinical scale for defining RBD severity in participants of the North American Prodromal Synucleinopathy (NAPS) consortium
Busicescu, Andrea , Lee‐Iannotti, Joyce , Rangan, Pooja , Ju, Yo‐El S. , Choudhury, Parichita , Shprecher, David , Boeve, Bradley F. , Postuma, Ronald B.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S7 | Pages: No page available

10.1002/alz.063998 Get It

AbstractBackgroundREM Sleep Behavior Disorder (RBD) is a prodromal marker of α‐synucleinopathies with no standardized tool for assessing severity in clinical or research practice. RBD severity may have implications in measuring risk of phenoconversion, monitoring response to treatment and clinical trial design. This study assessed the validity of the RBD symptom severity scale (RBDSSS) and its correlation to the clinical global impression of severity (CGI‐S) in a cohort of participants enrolled in the North American Prodromal Synucleinopathy (NAPS) Consortium.MethodParticipants and their bedpartners enrolled in the NAPS cohort filled out an 8‐item questionnaire, developed by the International RBD Study Group, assessing frequency and severity of dreams, vocalizations, movements, and injuries associated with RBD, with higher scores indicating more severe symptoms. The CGI‐S is a 7‐point scale ranging from normal (1) to most severely ill (7) and was completed by a clinician based on an independent interview with the participant ± their bedpartners. Total scores for participant (RBDSSS‐PT) and bed partner (RBDSSS‐BP) questionnaires were derived by multiplying frequency and severity scores for each feature, then summing the products for possible maximum scores of 54 and 38 respectively.ResultThis cohort (n = 212) was predominantly male (82.5%) with a mean ± SE age of 65.16 ± 1.46 years. The median (interquartile range) for RBDSSS‐PT, RBDSSS‐BP and CGI‐S was 11 (4‐17), 8 (4‐14.3) and 3 (3‐4), respectively. Spearman’s rank correlation coefficients (rs) were as follows: RBDSSS‐PT vs. RBDSSS‐BP, rs = 0.579; RBDSSS‐PT vs. CGI‐S, rs = 0.642; RBDSSS‐BP vs. CGI‐S, rs = 0.487 (all P<0.0001). RBDSSS‐BP scores were significantly lower in women (6 vs. 9, Chi‐Square p = 0.009) while there were no differences in RBDSSS‐PT scores by sex. (9 vs. 11, p = 0.473).ConclusionA moderate correlation was observed between RBDSSS‐PT and RBDSSS‐BP suggesting good construct validity for the scale. CGI‐S correlated most with RBDSSS‐PT and had a weaker association with RBDSSS‐BP. Women had lower severity scores as reported by bed partners unlike their self‐reported scores, indicating possible sex differences in perceived RBD severity.
2129. Maternal Transmission of SARS-CoV-2-specific Antibodies, but not Cytokines/Chemokines to Neonates Following Infection and Vaccination During Pregnancy
Monroe, Jonathon M. , Punia, Sohan, Enninga, Elizabeth A, Fedyshyn, Yaroslav , Fedyshyn, Bohdana , Lemens, Maureen A. , Littlefield, Dawn, Sintim-Aboagye, Elise, Plazas, Maria C. Mejia , Yamaoka, Satoko , Sun, Jie , Chakraborty, Rana , Quach, Huy Quang , Enninga, Elizabeth Ann L. , Ebihara, Hideki , Pandey, Akhilesh , Sun, Jie , Johnson, Erica L. , Kennedy, Richard B. , Theiler, Regan N.

Mayo Clinic

Open Forum Infectious Diseases | December 15, 2022 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofac492.1750 Get It

Abstract Background Despite extensive studies of human immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) vaccination, research examining protective correlates of vertical transmission following maternal exposure in pregnancy remain limited. Here, we characterized antibody and cytokine responses in maternal and cord blood following infection or vaccination at various timepoints during gestation. Methods Spike S1 protein-specific binding antibodies and antibodies capable of blocking the interaction between the receptor binding domain (RBD) and the angiotensin converting enzyme 2 (ACE2) were measured in maternal and cord blood by ELISA. Serum concentrations of 74 cytokines/chemokines were measured by multiplex assay. Humoral responses and cytokine levels from matched maternal and fetal cord sera were compared and examined for potential correlations. Results We observed a highly significant correlation between Spike S1-specific antibody titer and RBD-ACE2 blocking antibody activity between maternal and fetal cord serum (p &lt; 2.2e-16, R &gt; 0.90). Blocking antibody activity was significantly higher for mothers infected during the 3rd trimester compared to earlier trimesters; however, vaccinated mothers developed and transferred higher antibody titers with greater RBD-ACE2 blocking antibody activity to their neonates than infected mothers. Furthermore, vaccine-induced Spike S1 IgG transfer ratios (fetal cord/maternal) were significantly higher than those induced by infection (p = 0.002). Multiplex assay showed significantly elevated levels of 33 cytokines/chemokines, mainly pro-inflammatory in infected maternal serum samples, while the paired fetal cord samples exhibited an anti-inflammatory cytokine predominance. Conclusion Our data support selective vertical transmission of potentially protective humoral responses against SARS-CoV-2, especially following vaccination in the 3rd trimester. The anti-inflammatory cytokine predominance in cord blood that persists despite maternal SARS-CoV-2 infection may offset the adverse outcomes of inflammation in pregnancy for the neonate. Disclosures All Authors: No reported disclosures.
Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia
Jin, Qi , Gutierrez-Diaz, Blanca T. , Zhou, Yalu, Narang, Sonali , Fijalkwoski, Igor, Borin, Cristina , Laere, Jolien Van, Payton, Monique A. , Cho, Byoung-Kyu , Han, Cuijuan , Sun, Limin , Serafin, Valentina , Yacu, George, Veltri, Giulia , Dreveny, Ingrid , Goo, Young Ah , Safgren, Stephanie L. , Tsai, Yi-Chien , Bornhäuser, Beat , Suraneni, Praveen, Gaspar‐Maia, Alexandre , Kandela, Irawati , Crispino, John D. , Ntziachristos, Panagiotis , Gutierrez Diaz, Blanca , Pieters, Tim , Narang, Sonali , Fijalkwoski, Igor , Borin, Cristina , Payton, Monique , Cho, Byoung-Kyu , Han, Cuijuan , Sun, Limin , Serafin, Valentina , Von Loocke, Wouter , Veltri, Giulia , Dreveny, Ingrid , Ben-Sahra, Issam , Safgren, Stephanie L , Bornhauser, Beat , Gaspar-Maia, Alexandre , Van Vlierberghe, Pieter , Tsirigos, Aristotelis , Ntziachristos, Panagiotis , Crispino, John D , Jin, Qi , Basso, Giuseppe , Vlierberghe, Pieter Van , Tsirigos, Aristotelis

Mayo Clinic

Science Advances | December 9, 2022 | Volume: 8 | Issue: 49 | Pages: No page available

10.1126/sciadv.abq8437 | PMID 36490346 Get It

Dysregulation of kinase signaling pathways favors tumor cell survival and therapy resistance in cancer. Here, we reveal a posttranslational regulation of kinase signaling and nuclear receptor activity via deubiquitination in T cell acute lymphoblastic leukemia (T-ALL). We observed that the ubiquitin-specific protease 11 (USP11) is highly expressed and associates with poor prognosis in T-ALL. USP11 ablation inhibits leukemia progression in vivo, sparing normal hematopoiesis. USP11 forms a complex with USP7 to deubiquitinate the oncogenic lymphocyte cell–specific protein-tyrosine kinase (LCK) and enhance its activity. Impairment of LCK activity leads to increased glucocorticoid receptor (GR) expression and glucocorticoids sensitivity. Genetic knockout of USP7 improved the antileukemic efficacy of glucocorticoids in vivo. The transcriptional activation of GR target genes is orchestrated by the deubiquitinase activity and mediated via an increase in enhancer-promoter interaction intensity. Our data unveil how dysregulated deubiquitination controls leukemia survival and drug resistance, suggesting previously unidentified therapeutic combinations toward targeting leukemia.
Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III Nation
Litzow, Mark R. , Sun, Zhuoxin , Paietta, Elisabeth , Mattison, Ryan J. , Rowe, Jacob M. , Zhang, Yanming , Wieduwilt, Matthew J. , Liedtke, Michaela , Bergeron, Julie , Pratz, Keith W. , Dinner, Shira, Gore, Steven D. , Bhatnagar, Bhavana , Jeyakumar, Deepa , Little, Richard F. , Luger, Selina M. , Tallman, Martin S. , Lazarus, Hillard M. , Arber, Daniel A. , Mullighan, Charles G. , Willman, Cheryl L. , Frey, Noelle V. , Atallah, Ehab , Uy, Geoffrey L. , Lin, Tara L.

Mayo Clinic

Blood | December 7, 2022 | Volume: 140 | Issue: Supplement 2 | Pages: LBA-1-LBA-1

10.1182/blood-2022-171751 Get It

S37 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results
Lacerda, Ana P. , D’Haens, Geert , Reinisch, Walter, Louis, Édouard , Chen, Minhu , Boland, Brigid S. , Dubcenco, Elena, Feng, Tian, Panés, Julián , Loftus, Edward V. , Peyrin‐Biroulet, Laurent , Panaccione, Remo , Reinisch, Walter , Louis, Edouard , Nakase, Hiroshi , Begun, Jakob , Liu, Jianzhong , Mohamed, Mohamed‐Eslam F. , Feng, Tian, Colombel, Jean‐Frédéric

Mayo Clinic

American Journal of Gastroenterology | December 5, 2022 | Volume: 117 | Issue: 12S | Pages: S10-S10

10.14309/01.ajg.0000897656.25080.34 Get It

Effects of age and time since injury on traumatic brain injury blood biomarkers: a TRACK-TBI study
Puccio, Ava M. , Korley, Frederick K. , Okonkwo, David O. , Puffer, Ross C. , Yuh, Esther L. , Yue, John K. , Sun, Xiaoying, Taylor, Sabrina R. , Mukherjee, Pratik , Jain, Sonia , Manley, Geoffrey T. , Investigators, the TRACK-TBI, Feeser, V. Ramana, Ferguson, Adam R. , Gaudette, Etienne, Gopinath, Shankar P. , McCrea, Michael , Merchant, Randall E., Robertson, Claudia S. , Vassar, Mary J. , Zafonte, Ross , Mukherjee, Pratik , Gardner, Raquel C. , Wang, Kevin , Diaz‐Arrastia, Ramon , Investigators, the TRACK-TBI, Gaudette, Etienne, Keene, C. Dirk , Madden, Christopher, Martin, Alastair J. , Ngwenya, Laura Benjamin , Temkin, Nancy R.

Mayo Clinic

Brain Communications | November 30, 2022 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcac316 | PMID 36642999 Get It

Abstract Older adults have the highest incidence of traumatic brain injury globally. Accurate blood-based biomarkers are needed to assist with diagnosis of patients across the spectrum of age and time post-injury. Several reports have suggested lower accuracy for blood-based biomarkers in older adults, and there is a paucity of data beyond day-1 post-injury. Our aims were to investigate age-related differences in diagnostic accuracy and 2-week evolution of four leading candidate blood-based traumatic brain injury biomarkers—plasma glial fibrillary acidic protein, ubiquitin carboxy-terminal hydrolase L1, S100 calcium binding protein B and neuron-specific enolase—among participants in the 18-site prospective cohort study Transforming Research And Clinical Knowledge in Traumatic Brain Injury. Day-1 biomarker data were available for 2602 participants including 2151 patients with traumatic brain injury, 242 orthopedic trauma controls and 209 healthy controls. Participants were stratified into 3 age categories (young: 17–39 years, middle-aged: 40–64 years, older: 65–90 years). We investigated age-stratified biomarker levels and biomarker discriminative abilities across three diagnostic groups: head CT-positive/negative; traumatic brain injury/orthopedic controls; and traumatic brain injury/healthy controls. The difference in day-1 glial fibrillary acidic protein, ubiquitin carboxy-terminal hydrolase L1 and neuron-specific enolase levels across most diagnostic groups was significantly smaller for older versus younger adults, resulting in a narrower range within which a traumatic brain injury diagnosis may be discriminated in older adults. Despite this, day-1 glial fibrillary acidic protein had good to excellent performance across all age-categories for discriminating all three diagnostic groups (area under the curve 0.84–0.96; lower limit of 95% confidence intervals all &gt;0.78). Day-1 S100 calcium-binding protein B and ubiquitin carboxy-terminal hydrolase L1 showed good discrimination of CT-positive versus negative only among adults under age 40 years within 6 hours of injury. Longitudinal blood-based biomarker data were available for 522 hospitalized patients with traumatic brain injury and 24 hospitalized orthopaedic controls. Glial fibrillary acidic protein levels maintained good to excellent discrimination across diagnostic groups until day 3 post-injury irrespective of age, until day 5 post-injury among middle-aged or younger patients and until week 2 post-injury among young patients only. In conclusion, the blood-based glial fibrillary acidic protein assay tested here has good to excellent performance across all age-categories for discriminating key traumatic brain injury diagnostic groups to at least 3 days post-injury in this trauma centre cohort. The addition of a blood-based diagnostic to the evaluation of traumatic brain injury, including geriatric traumatic brain injury, has potential to streamline diagnosis.
The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification
Foran, James M. , Tandra, Anand, Mattour, Ahmad, Perkins, Andrew C. , Rodríguez‐Macías, Gabriela , Sibai, Hassan , Sun, Yan , Potluri, Jalaja , Harb, Jason G., How, Jonathan, Perkins, Andrew C , Passamonti, Francesco , Stefano, Valerio De , Fox, María Laura , McMullin, Mary Frances , Qin, Qin

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 583-585

10.1182/blood-2022-157949 Get It